Wako Diagnostics

Fujifilm Wako Diagnostics is a premier provider of high-quality diagnostic solutions, specializing in the development of biomarkers for liver disease and oncology. The company is widely recognized for its proprietary μTASWako platform, an automated microfluidic system that performs highly sensitive immunoassays for the risk assessment of hepatocellular carcinoma. Following its acquisition by Fujifilm in 2017, the company has leveraged its deep expertise in chemical reagents and clinical diagnostics to support global healthcare needs. Their portfolio includes FDA-cleared tests for AFP-L3 and DCP, which are critical tools for monitoring patients with chronic liver disease. Beyond diagnostics, the company provides a broad range of laboratory reagents and specialty chemicals for research and industrial use.